Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17419100 | 0.89 | CYP11B2 (0.49) | PDE3BPDE3AALOX5CYP11B1CYP11B2 | |
| SCHEMBL31161251 | 0.84 | PDE3B (0.43) | PDE3BPDE3AALOX5CYP11B1CYP11B2 | |
| SCHEMBL16932318 | 0.84 | PDE3B (0.43) | PDE3BPDE3AALOX5CYP11B1CYP11B2 | |
| SCHEMBL13266727 | 0.83 | PDE3B (0.40) | PDE3BPDE3AALOX5CYP11B1CYP11B2 | |
| SCHEMBL30219059 | 0.79 | LPL (0.40) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL15796914 | 0.78 | PRKCQ (0.34) | ROCK1CSF1RIDO1TDO2 | |
| SCHEMBL21671946 | 0.78 | POLB (0.40) | TSHRHTT | |
| SCHEMBL30869649 | 0.78 | LPL (0.42) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL14822226 | 0.78 | BACE1 (0.39) | ROCK1LPLLIPGCSF1RIDO1 | |
| SCHEMBL16362077 | 0.77 | CYP11B2 (0.38) | PDE3BPDE3AALOX5CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | PDE3B 2642/4885PDE3A 3109/4885ALOX5 399/4885 |
| US-20100286118-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 | PDE3B 247/4885PDE3A 345/4885ALOX5 3478/4885 |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PDE3B 2209/4885PDE3A 3057/4885ALOX5 1855/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | PDE3B 2209/4885PDE3A 3057/4885ALOX5 1855/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PDE3B 2209/4885PDE3A 3057/4885ALOX5 1855/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | PDE3B 2665/4885PDE3A 2090/4885ALOX5 3174/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | PDE3B 2209/4885PDE3A 3057/4885ALOX5 1855/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | PDE3B 2206/4885PDE3A 2339/4885ALOX5 1888/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PDE3B 2209/4885PDE3A 3057/4885ALOX5 1855/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | PDE3B 563/4885PDE3A 1049/4885ALOX5 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.